Strategic Collaborations Will Propel Big Changes in the Global Antisense and RNAi Therapeutics Market from 2015 to 2019: TechNavio

Strategic Collaborations Will Propel Big Changes in the Global Antisense and RNAi Therapeutics Market from 2015 to 2019: TechNavio

<0> TechNavio ResearchJes EllacottUS: +1-630-333-9501UK: +44 208 123 1770Media & Marketing Executive </0>

The will post a CAGR of 26.79 percent from 2015-2019, according to a new report from TechNavio.

The new report emphasizes the growth of strategic collaborations and licensing activities, which are contributing to the development of antisense and RNAi therapeutics and technology platforms. Partnering on these developments are academic institutions as well as pharmaceutical and biotechnology companies, resulting in many rising start-ups.

“The market is currently witnessing heightened collaboration between big pharmaceutical companies like Roche, Pfizer, GSK and Genzyme, and RNAi-based therapeutics developers like Isis and Alnylam Pharmaceuticals,” says Faisal Ghaus, Vice President of TechNavio.

“Alnylam Pharmaceuticals formed an alliance with Genzyme to develop and commercialize RNAi therapeutics, which led to the introduction of ALN-TTRsc and Patisiran for the treatment of ATTR in the APAC region.”

Following a similar trend in the US, Genzyme has begun commercializing Kynamro, a lead product of Isis Pharmaceuticals. The increased number of licensing activities is expected to propel further growth in the Global Antisense and RNAi Therapeutics Market through the projected period.

Key Information Covered in the Report:

currently has more than 3000 market research reports on a huge range of topics, including 300+ reports on global therapeutics markets:

If you are interested in more information, please contact our media team at .

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.